UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of August 2024
Commission File Number: 001-38104
IMMURON LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes ☐ No
☒
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-
IMMURON LIMITED
EXPLANATORY NOTE
Immuron Limited (the “Company”) published
one announcement (the “Public Notices”) to the Australian Securities Exchange on August 16, 2024 titled:
|
- |
“New US DoD Research Award to develop enhanced Travelan” |
A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.
This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
EXHIBITS
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
IMMURON LIMITED |
|
|
Date: August 16, 2024 |
By: |
/s/ Phillip Hains |
|
|
Phillip Hains |
|
|
Company Secretary |
3
Exhibit 99.1
Immuron Announces New U.S. Department of Defense
Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
Highlights:
$3.5 (USD $2.3) million funding for NMRC and WRAIR approved
by the U.S. Department of Defense to advance the development of Travelan.
Melbourne, Australia, August 16, 2024:
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce
the funding of a new research agreement for the Naval Medical Research Command (NMRC), and Walter Reed Army Institute of Research (WRAIR)
Silver Spring, MD, USA.
The focus of this new research agreement
is to develop an enhanced formulation of Travelan potentially expanding the coverage of the product as a therapeutic measure against endemic
military relevant diarrheal pathogens. This work will utilize the extensive experience of the US Department of Defense human infectious
disease vaccine programs and will target key protective antigens of the major enteric bacterial pathogens Campylobacter, Shigella
and Entertoxigenic E. coli strains not present in the current product formulation.
Immuron will now negotiate a sub award
for collaboration with NMRC and WRAIR to advance this research.
The U.S Department of Defense has recognized
the benefits of Immuron’s technology platform and has an established long-standing relationship with Immuron to evaluate the commercial
over-the-counter bovine colostrum product Travelan for its specificity and effectiveness against diarrheal pathogens. As an extension
of the current Shigella (WRAIR), ETEC and Campylobacter (NMRC) research programs the goal of this award is to identify and define pathways
to formulate, characterize and perform pre-clinical testing of a military-relevant combined colostrum product.
Infectious diarrhea is the most common
illness reported by travelers visiting developing countries and among US troops deployed overseas as indicated by the 2019 Department
of Defense (DoD) Infectious Disease Threats Prioritization Panel. The morbidity and associated discomfort stemming from diarrhea decreases
daily performance, affects judgment, decreases morale and declines operational readiness. The first line of treatment for infectious diarrhea
is the prescription of antibiotics. Unfortunately, in the last decade, several enteric pathogens have demonstrated increasing resistance
to commonly prescribed antibiotics. In addition, traveler’s diarrhea is now recognized by the medical community to result in post-infectious
sequelae, including post-infectious irritable bowel syndrome (IBS) and several post-infectious autoimmune diseases. A preventative treatment
that defends against infectious enteric diseases is a high priority objective for the US Military.
This release has been authorised by the directors of Immuron Limited.
- - - END - - -
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024069975/ex99-1_002.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024069975/ex99-1_003.jpg)
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph: +61
(0)3 9824 5254
info@immuron.com
About Travelan®
Travelan® is an
orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive
tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified
tabletised preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria
and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan® is a listed
medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea,
reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural
health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan®
is sold as a dietary supplement for digestive tract protection.
About Travelers’ diarrhea
Travelers’ diarrhea is a gastrointestinal
infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic
bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter
spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery
organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with travelers’ diarrhea
as they may be contracted while travelling and initial symptoms are often indistinguishable.
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN),
is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for
the treatment of inflammatory mediated and infectious diseases.
For more information visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release
may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our
growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are
based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic
agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting
and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our
ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional
funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is
based, except as required by law.
Acknowledgment
This work was supported by the U.S.
Army Medical Research and Development Command (USAMRDC), through the Joint Warfighter Medical Research Program (JWMRP) under Award Number
JW230174 funded for a total of $2,298,359. Opinions, interpretations, conclusions, and recommendations are those of the author and are
not necessarily endorsed by the Department of Defense. In conducting research using animals, the investigator(s) adhered to the laws of
the United States and regulations of the Department of Agriculture. In the conduct of research involving hazardous organisms or toxins,
the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024069975/ex99-1_002.jpg)
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Aug 2023 to Aug 2024